IrvingKentLohMDFACC FAHA FCCP FACP(He/Him)

PubMed

• 30 citations
  National heart, lung, and blood institute type II coronary intervention study: Design, methods, and baseline characteristics☆
  John F. Brensike, Sheryl F. Kelsey, Eugene R. Passamani, Marian R. Fisher, John M. Richardson
  Controlled Clinical Trials. 1982-06-01
• 331 citations
  The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention S...
  Robert I. Levy, John F. Brensike, S E Epstein, S. F. Kelsey, Eugene R. Passamani
  Circulation. 1984-02-01
• 2 citations
  Advancing the care of individuals with cancer through innovation & technology: Proceedings from the cardiology oncology innovation summit 2020 and 2021.
  Sherry-Ann Brown, Craig Beavers, Brenton Bauer, Richard K Cheng, Generika Berman
  American Heart Journal Plus. 2024-02-01

Journal Articles

• Use of Simvastatin Treatment in Patients with Combined Hyperlipidemia in Clinical Practice.  
  Simvastatin Combined Hyperlipidemia Registry Group, Arch Fam Med
• Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure.  
  Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE), New England Journal of Medicine
• Moexipril Versus Captopril in Patients with Mild to Moderate Hypertension.  
  M Stimpel, B Koch, T Jansen, A Fox, I Loh, J Cardiovasc Pharmacol
• Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients with Hypercholesterolemia (The CURVES Study).  
  CURVES Investigators, Am J Cardiol
• A Dose-Dependent Increase in Mortality with Vesnarinone Among Patients with Severe Heart Failure.  
  Vesnarinone Trial Investigators, New England Journal of Medicine
• Hobbs RE. Results of the ATLAS Study – high or low doses of ACE inhibitors for heart failure?  
  ATLAS Trial Investigators, Cleve Clin J Med
• Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure.  
  ATLAS Study Group, Circulation
• Comparative Effects of Candesartan Cilexetil and Losartan in Patients with Systemic Hypertension.  
  CANDLE Trial Investigators, Heart Disease
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HR).  
  MERIT-HF Study Group, THE LANCET
• Clinical trials back growing use of beta-blockade in heart failure.  
  IK Loh, Cardiology Review
• Effect of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Interve...  
  MERIT-HF Study Group, JAMA
• Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Hypercholesterolaemia: the Pivotal Placebo- controlled Clinical Trial.  
  Cerivastatin Study Group, J International Medical Research
• Addition of Zatebradine, a Direct Sinus Node Inhibitor, Provides No Greater Exercise Tolerance Benefit in Patients With Angina Taking Extended-Release Nifedipine: Re...  
  Zatebradine Study Group, J Am Coll Card
• Comparative Efficacy of Olmesartan, Losartan, Valsartan and Irbesartan in the Control of Essential Hypertension.  
  CS-866 Study Group, Journal of Clinical Hypertension
• Cardiovascular morbidity and mortality n the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.  
  LIFE Study Group, THE LANCET
• Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial).  
  STELLAR Study Group, Am. J. Cardiol
• Comparison of the Efficacy of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin in Achieving Lipid Goals; Results from the STELLAR Trial.  
  STELLAR Study Group, Current Medical Research and Opinions
• argeted Anticytokine Therapy in Patients with Chronic Heart Failure; Clinical Investigation and Reports.  
  RENEWAL Study Group, Circulation
• Information Technology at the Point- of-Care Will Improve Quality and Outcome: Methodology.  
  IK Loh, Sutherland J, Ash A, Circulation Supplement
• Dose-comparison Study of the Combination of Ezetimibe and Simvastatin Versus Atorvastatin in Patients with Hypercholesterolemia: the Vytorin Versus Atorvastatin Study.  
  VYVA Study Group, Am. Heart J
• Achieving LDL cholesterol, non-HDL cholesterol, and apoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastati...  
  Mercury II Study Group, Am. Heart J
• Exceptional early blood pressure control rates: The ACCOMPLISH trial.  
  Accomplish Investigators, Blood Pressure
• Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein.  
  JUPITER Study Group, New Engl. J. Med
• Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients with Stable Coronary Artery Disease.  
  ASSERT Study Group, J Am Coll Cardiol
• Effects of cholestyramine therapy on progression of coronary arteriosclerosis: Results of the NHLBI type II coronary intervention study.  
  JF Brensike, Levy RI, Kelsey S, Passamani E, Richardson R, Loh IK, Stone NJ, Aldrich R, Battaglini J, Moriarty D, Fisher M, Friedman L, Friedewald W, Detre K, Epstei..., Circulation
• Join now to see all

Abstracts/Posters

• Moexipril Versus Captopril in Patients with Mild to Moderate Hypertension.
  Loh IK, Tenth Scientific Meeting of the American Society of Hypertension; New York Hilton/Towers, New York, NY

Lectures

• Cardiovascular Clinical Trials. 
  Desert Hospital, Palm Springs, California
• Randomized Clinical Trials in the Evaluation of Cardiovascular Therapies. 
  Syntex Corporation; Palo Alto, CA
• Faculty, Symposium on the Management of High-Risk Patients. 
  Cedars-Sinai Medical Center; Century Plaza Hotel; Century City, CA
• Faculty, Future Focus - 2004: Medical Ethics. 
  Conejo Future Foundation/Calif. Lutheran College
• Faculty, Ventura County Hospitals Council Seminar: Medical Ethics. 
  Harbortown; Ventura, CA
• Featured Guest, "Let's Talk". 
  Satellite radio broadcast discussing Bio-medical Ethics
• Faculty, Ventura County Chapter, American Diabetes Association: Keynote Address "Preventing Heart Disease". 
  Camarillo, CA
• Grand Rounds, Rancho Los Amigos, USC: New Developments in Management of Hypercholesterolemia. 
  Los Angeles, CA
• cientific Session, Ojai Community Hospital: Hyperlipidemia - Assessment and Treatment. 
  Ojai, CA
• Faculty - Symposium on Chronic Diseases: Hypercholesterolemia 1988. 
  Universal City, CA
• Scientific Session: LDL Cholesterol: the Standard for Treatment of Hypercholesterolemia. 
  Magic Valley Medical Center Twin Falls, ID
• Scientific Session, Santa Ynez Medical Center: The Current Assessment and Management of Hypercholesterolemia and the Role of HDL. 
  Solvang, CA
• HDL in the Assessment and Management of Dyslipidemia. 
  Scientific Session, Humana West Hills Medical Center, West Hills, CA
• Cholesterol Management in Clinical Practice Universal Hilton; Vital Issues in Medicine. 
  Guest Chairman -Los Angeles Teleconference
• Faculty - Symposium: Lipid Regulation and Risk Prevention: HDL Cholesterol - An important independent risk factor for coronary heart disease. 
  Marriott Hotel, Woodland Hills, CA
• The current status of anti-arrhythmic therapy after the Cardiac Arrhythmia Suppression Trial 
  Scientific Session, Encino Hospital; Encino, CA
• Oderator - Symposium: Lipid Regulation and Risk Prevention. 
  Universal Sheraton Hotel, Universal City, CA
• Moderator: Advances in Cardiology. 
  Hyatt Westlake Plaza Hotel; Westlake Village, CA
• Faculty, Tenth Annual Professional Symposium, American Lung Association of Ventura County: Medical Ethics and Dying. 
  Hilton Hotel, Oxnard, CA
• Faculty - Symposium: Lipid Regulation and Risk Prevention: HDL Cholesterol - An important independent risk factor for coronary heart disease. 
  Four Seasons Hotel, Beverly Hills, CA
• Faculty - Southwest Lipid & Metabolics Working Group: New [hypolipidemic] Agents for the Future. 
  Four Seasons Hotel; Newport Beach, CA
• Moderator: Treatment of Hyperlipidemia. 
  Saddle Peak Lodge; Calabasas, CA
• Scientific Session, Central California Heart Institute: Regression of Coronary Artery Disease. 
  Bakersfield, CA
• Current Assessment and Management of Dyslipidemia and Regression of Coronary Heart Disease. 
  Scientific Conference, Los Robles Regional Medical Center, Thousand Oaks, CA
• Moderator: Treatment of Hyperlipidemia. 
  Lautrec Restaurant; Woodland Hills, CA
• Join now to see all

Other

• Risk Factors in Premature Coronary Disease (Interview by Deborah Norville) 
  Loh IK, Guest
  NBC Studios, New York
• Radio Interview: Health Care Reform: Initiatives to reduce federal impediments to the delivery of health care. 
  Loh IK
  The White House, Washington
• Innovations in pharmaceuticals 
  IK Loh, Street Journal
  http://online.wsj.com/article/